US Stock Insider Trading | PROCEPT BioRobotics Discloses 9 Insider Transactions on March 9

K-LinePoet · 2026-03-16T10:31:06+00:00

On March 9, 2026, Desai Antal Rohit, a director of PROCEPT BioRobotics, made multiple stock purchases, totaling 142,500 shares. Additionally, executives Waters Kevin and Nouri Alaleh conducted stock sales on the same day. The company focuses on developing surgical robotic systems for urology.

K-LinePoet

2026-03-16 10:31:06

Abstract generation in progress

On March 9, 2026, PROCEPT BioRobotics (PRCT) disclosed nine insider trading transactions. Director Desai Antal Rohit purchased 13,000 shares on March 9, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 9, 2026	Executive	Waters Kevin	March 6, 2026	Sell	6,721	23.70	$159,300
March 9, 2026	Director	Desai Antal Rohit	March 9, 2026	Buy	1,300	25.42	$33,000
March 9, 2026	Director	Desai Antal Rohit	March 5, 2026	Buy	24,700	26.41	$653,500
March 9, 2026	Director	Desai Antal Rohit	March 6, 2026	Buy	106,600	23.33	$2,485,700
March 9, 2026	Director	Desai Antal Rohit	March 6, 2026	Buy	53,800	24.10	$1,295,800
March 9, 2026	Director	Desai Antal Rohit	March 9, 2026	Buy	53,800	24.91	$1,340,300
March 9, 2026	Director	Desai Antal Rohit	March 5, 2026	Buy	143,500	25.44	$3,625,000
March 9, 2026	Director	Desai Antal Rohit	March 9, 2026	Buy	43,600	24.08	$1,049,500
March 9, 2026	Executive	Nouri Alaleh	March 6, 2026	Sell	6,892	23.70	$163,400
August 15, 2025	Director	Desai Antal Rohit	August 14, 2025	Buy	26,700	1.33	$35,600

[Company Information]

PROCEPT BioRobotics Corporation was incorporated in California in 2007. In April 2021, the company re-registered in Delaware. It is a commercial-stage surgical robotics company focused on advancing patient care through the development of transformative solutions in urology. They develop, manufacture, and sell the AquaBeam robotic system, an advanced image-guided surgical robot used for minimally invasive urological procedures, initially focused on treating benign prostatic hyperplasia (BPH).

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.